The problem of multiple vaccines (click to open)

The aluminum problem (click to open)

In 1981, the US Food and Drug Administration (FDA) authorized a plasma-derived hepatitis B vaccine that contained antigens taken from infected individuals. This vaccine was later withdrawn from the market because, like all vaccines produced from human blood, it was capable of transmitting unwanted and potentially dangerous viruses. In 1986, the first of a series of genetically modified (recombinant DNA) vaccines was authorized.
Numerous studies have investigated the probability that those who received the plasma-derived vaccine could also have received unwanted viruses, especially HIV, the precursor to AIDS.^(1-2) Furthermore, clinical studies to attest to the safety of the current hepatitis B vaccine were only carried out on 147 healthy children monitored for just 5 days after administration⁽³⁾ This is not a large enough sample nor a long enough period to determine the true incidences of adverse events. The manufacturing companies themselves have admitted that "widespread use of the vaccine could lead to the emergence of adverse reactions not observed in clinical trials".⁽⁴⁾
Even adult subjects were monitored for only five days after vaccination and, despite this, systemic effects such as arthralgia, myalgia, paraesthesia, back and neck pain, lymphadenopathy, headache, fever, malaise, chills, vomiting were still reported. , diarrhea, abdominal pain, upper respiratory tract infections, earache and hypotension.⁽⁵⁾
Despite the official technical data sheets, and other documents that propagate⁽⁶⁾ the hepatitis B vaccine, tend to minimize or deny serious adverse reactions, numerous studies published in medical and scientific journals around the world and reports forwarded to VAERS⁽⁷⁾ confirm various pathologies as a consequence of vaccination. Some of these studies are summarized below.

Arthritis

In 1990, soon after the introduction of the hepatitis B vaccine, the British Medical Journal documented a link between the vaccine and polyarthritis, a painful inflammation of five or more joints.⁽⁸⁾ The same year the Journal of Rheumatology published a paper on reactive arthritis after hepatitis B vaccination.⁽⁹⁾

In 1994, the British Journal of Rheumatology released data documenting rheumatoid arthritis after the vaccine⁽¹⁰⁾ and the BMJ published three further reports confirming the link between the vaccine and reactive arthritis.^(11-12) In 1995, two studies were published in the Scandinavian Journal of Rheumatology confirming cases of post-vaccination arthritis^(13-14) and that same year the Irish Medical Journal documented the link with arthropathy.⁽¹⁵⁾ In 1997, the British Journal of Rheumatology published two other studies documenting several cases of inflammatory polyarthritis after the vaccine^(16-17) and in 1998 the Journal of Rheumatology again confirmed rheumatoid arthritis.⁽¹⁸⁾ Also in that year, the French magazine Revue de Médecine Interne published a study on Still's disease with onset in adulthood - a rare and painful type of arthritis - after vaccination for hepatitis A and B.⁽¹⁹⁾ In 1999, Rheumatology documented rheumatological disorders after the vaccine⁽²⁰⁾ and in 2000 the American College of Rheumatology published research in the peer-reviewed journal Arthritis & Rheumatology that documented Sjogren's syndrome - a rare form of chronic arthritis - after hepatitis B vaccination.⁽²¹⁾

Autoimmune and neurological diseases including multiple sclerosis

In 1983, the New England Journal of Medicine published a study demonstrating the onset of polyneuropathy - simultaneous malfunction of numerous nerves - after hepatitis B vaccination.⁽²²⁾ In 1988, the American Journal of Epidemiology reported multiple “neurological adverse events” after the vaccine including numerous cases of Guillain-Barré syndrome, lumbar radiculopathy, brachial plexus neuropathy, optic neuritis, and transverse myelitis.⁽²³⁾ The same year, the journal Archives of Internal Medicine documented myasthenia gravis - a severe chronic autoimmune neuromuscular disease - again after hepatitis B vaccination.⁽²⁴⁾
In 1991 The Lancet published a report documenting central nervous system demyelination after the vaccine⁽²⁵⁾ and in 1992 Nephron released data linking vaccination to systemic lupus erythematosus, a chronic autoimmune disease that affects multiple organs.⁽²⁶⁾ Also in 1992, the journal Clinical Infectious Diseases published a study linking Evans syndrome - a rare autoimmune and blood disease with a high mortality rate - to the vaccine.⁽²⁷⁾ and the French magazine Thérapie published a study on "peripheral facial paralysis" again after administration of the drug.⁽²⁸⁾ Additionally, Infectious Disease News released a report stating numerous cases of neurological damage resembling multiple sclerosis⁽²⁹⁾ and in 1993 an article appeared in the Journal of Hepatology on transverse myelitis - inflammation of the spinal cord - after anti-hepatitis B vaccination.⁽³⁰⁾ That same year the French newspaper La Nouvelle Presse Médicale published data confirming post-vaccination "acute myelitis"⁽³¹⁾ and Clinical Infectious Diseases documented “classical multiple sclerosis.”⁽³²⁾ In 1994, Archives of Pediatrics and Adolescent Medicine released data linking lupus to the vaccine⁽³³⁾ and the journal Acta Neurologica Scandinavica published a report on acute cerebellar ataxia - severe loss of balance and motor coordination - after the vaccination in question.⁽³⁴⁾

In 1995, demyelination of the central nervous system was reported in the Journal of Neurology, Neurosurgery and Psychiatry⁽³⁵⁾ and in the American Journal of Neuroradiology myelitis. The authors of the latter study noted that adverse events of this nature may be under-reported because symptoms are late.⁽³⁶⁾ In 1996, both Nephron and the French journal Annales de Dermatologie et de Vénéréologie published studies attesting to the correlation between lupus erythematosus and the hepatitis B vaccine.^(37-38) The same year the Journal of Hepatology published a report on the link with leukoencephalitis, inflammation of the white matter of the brain.⁽³⁹⁾ In 1996, the New England Journal of Medicine documented postvaccination cryoglobulinemia, a rare autoimmune disease that impairs circulation, causes bleeding and other problems.⁽⁴⁰⁾
Vaccine-induced autoimmunity was certified in the Journal of Autoimmunity⁽⁴¹⁾ and in 1997 the Indian Journal of Pediatrics published a study linking Guillain-Barré syndrome, an autoimmune disease that causes nerve damage, muscle weakness and paralysis, to the vaccine.⁽⁴²⁾ The same year the Journal of Korean Medical Science documented acute myelitis⁽⁴³⁾ and the link with "mental nerve neuropathy" also emerged.⁽⁴⁴⁾

Data then appeared in JAMA on 46 people - mostly women - who had lost their hair after hepatitis B vaccination.⁽⁴⁵⁾
In 1998, both lupus erythematosus and thrombocytopenia were documented in vaccinated subjects⁽⁴⁶⁾ and in 1999 more alopecia in the American Journal of Gastroenterology.⁽⁴⁷⁾ The same year Autoimmunity documented a demyelinating polyneuropathy, while Neurology published data linking multiple sclerosis and encephalitis to the vaccine.^(48-49) Also in 1999, La Nouvelle Presse Médicale wrote about post-vaccination cervical myelitis⁽⁵⁰⁾ and in 2000 multiple sclerosis was discussed in Neurology.⁽⁵¹⁾ Also in 2000, the Journal of the Medical Association of Thailand wrote about Guillain-Barré syndrome after recombinant DNA hepatitis B vaccine⁽⁵²⁾ and in 2001 the Clinical Infectious Diseases documented leukoencephalitis.⁽⁵³⁾ In 2004, Neurology published a study showing the association between the vaccine and a statistically significant risk of multiple sclerosis;⁽⁵⁴⁾ in 2006 the Chinese Medical Journal also documented multiple sclerosis.⁽⁵⁵⁾ In 2008, Neurology released two studies showing a statistically significant correlation between hepatitis B vaccination in children and the development of pediatric multiple sclerosis (central nervous system demyelination) more than three years later.^(56-57)

Sensory impairment

Numerous medical and scientific publications have documented vision and hearing impairments after hepatitis B vaccination. For example, in 1987 The Lancet published a paper on uveitis – inflammation of the inner lining of the eye that often leads to blindness – after the vaccine.⁽⁵⁸⁾ In 1993, again in The Lancet, further data appeared documenting vision loss and eosinophilia - an allergic blood disease - again after vaccination.⁽⁵⁹⁾ In 1994 Optometry and Vision Science documented post-vaccination optic neuritis⁽⁵⁰⁾ and in 1995 epitheliopathy - a rare eye disorder that causes worsening vision - was discussed in the Archives of Ophthalmology.⁽⁶¹⁾ In 1996, The Lancet published a report documenting “central retinal vein occlusion” after the vaccine,⁽⁶²⁾ while in the American Journal of Ophthalmology bilateral white spot syndrome was mentioned - which causes loss of vision in both eyes.⁽⁶³⁾ Also in 1996, La Nouvelle Presse Médicale documented neuropapillitis - inflammation and deterioration of the optic nerve - after the vaccine⁽⁶⁴⁾ and another French journal, Annales d'Otolaryngologie et de Chirurgie Cervico-Faciale, mentioned hearing loss.⁽⁶⁵⁾ In 1997, La Nouvelle Presse Médicale then published two different studies documenting serious cases of central retinal vein occlusion after vaccination.^(66-67) The same year Nephrology Dialysis Transplantation confirmed the onset of optic neuritis after the vaccine⁽⁶⁸⁾ and International Ophthalmology certified “ophthalmic complications” in vaccinated subjects.⁽⁶⁹⁾ Also in 1997, the Annals of the New York Academy of Sciences and the international journal Auris, Nasus, Larynx noted post-vaccination hearing loss,^(70-71) while in 1998 the Journal of French Ophthalmology published data on epitheliopathy.⁽⁷²⁾ In 1999, the BMJ confirmed optic neuritis after hepatitis B vaccination⁽⁷³⁾ and Acta Ophthalmologica Scandinavica papilledema - swelling of the optic disc.⁽⁷⁴⁾ In 2001, a German magazine, Klinische Monatsblätter Für Augenheilkunde, also confirmed post-vaccination optic neuritis.⁽⁷⁵⁾

Blood diseases

In 1990, soon after the mass market introduction of the hepatitis B vaccine, the BMJ documented vasculitis, an inflammation of the blood vessels, after administration of the drug.⁽⁷⁶⁾ In 1993, the English magazine Thorax provided confirmation⁽⁷⁷⁾ and The Lancet published a study on eosinophilia, an allergic blood disease, again after vaccination.⁽⁷⁸⁾ In 1994 and 1995 The Lancet also documented thrombocytopenia - a serious disease that causes excessive bleeding, bruising and clotting problems.^(79-80) In 1998, the onset of thrombocytopenia was confirmed in numerous recently vaccinated patients⁽⁸¹⁾ also from the Scandinavian Journal of Infectious Diseases confirmed and Archives of Disease in Children published data confirming this disease as an adverse event of the vaccine.⁽⁸²⁾ In 1999, the European Journal of Pediatrics once again confirmed thrombocytopenia after both hepatitis B and MMR vaccines⁽⁸³⁾ and the same year the Journal of Rheumatology published two important studies of which the first had demonstrated the correlation between vaccine and vasculitis⁽⁸⁴⁾ and the second erythermalgia, vascular spasms in the hands and feet that cause pain and burning.⁽⁸⁵⁾ In 2000, Clinical and Experimental Rheumatology studied cases of polyarthritis nodosa⁽⁸⁶⁾ - a rare, systemic, necrotizing (cell-damaging) type of vasculitis - and the British Journal of Haematology documented severe pancytopenia - a dangerous reduction in red blood cells.⁽⁸⁷⁾ In 2001, the Journal of Rheumatology published additional data confirming the possibility of vasculitis after recombinant hepatitis B vaccine⁽⁸⁸⁾ and the Italian journal Haematologica confirmed thrombocytopenia as an adverse event.⁽⁸⁹⁾

Skin diseases

In 1989, the New England Journal of Medicine documented erythema nodosum — painful inflammation of the skin with soft bumps — after hepatitis B vaccination.⁽⁹⁰⁾ In 1993, the Journal of Rheumatology reported cases of both erythema nodosum and Takayasu arthritis – a rare form of vasculitis.⁽⁹¹⁾ The same year the Swedish journal Acta Dermato-Venereologica wrote about lichen ruber planus after vaccination⁽⁹²⁾ - an itchy rash on the skin characterized by thick, hard lesions close together that resemble algae or fungi growing on rocks. In 1994, the Archives of Dermatology also documented lichen planus after vaccination⁽⁹³⁾ and Pediatric Dermatology demonstrated a link to erythema multiforme.⁽⁹⁴⁾ In 1997, the Australasian Journal of Dermatology confirmed the “lichenoid reaction” (lichen planus) after the vaccine⁽⁹⁵⁾ and the Journal of the American Academy of Dermatology wrote about anethodermia⁽⁹⁶⁾ - localized wrinkling, loss of elasticity and atrophy of the skin - after vaccination. In 1998, the British Journal of Dermatology published two studies documenting post-vaccination skin diseases: one was on lichen planus⁽⁹⁷⁾ and the other on urticaria and angioedema,⁽⁹⁸⁾ allergic-based pathologies characterized by burning, stinging and painful swelling. In 1999, lichen planus was also mentioned in the International Journal of Dermatology⁽⁹⁹⁾ and in 2000, data confirming post-vaccination erythema multiforme were published in Clinical and Experimental Dermatology.⁽¹⁰⁰⁾ In the same year, the Nepal Journal of Dermatology again wrote about lichen planus after hepatitis B vaccination⁽¹⁰¹⁾ in 2001 the mention appeared in the Journal of the American Academy of Dermatology⁽¹⁰²⁾ while Pediatric Dermatology spoke of lichenoid eruption.⁽¹⁰³⁾

Diabetes liver and kidney diseases

In 1994 The Lancet documented liver dysfunction after hepatitis B vaccination⁽¹⁰⁴⁾ and in 1995 Clinical Nephrology published a study on nephrotic syndrome - kidney damage - again after vaccination.(105) In 1996 the New Zealand Medical Journal published two documents that correlated antihepatitis B to epidemics of insulin-dependent diabetes mellitus (IDDM). The authors found that in the three years following a newly introduced and very extensive mass vaccination campaign, there was a 60% increase in IDDM cases.^(106-107) In 1997, Intensive Care Medicine wrote about liver inflammation and acute respiratory disease after vaccination (108). In 2000, Pediatric Nephrology confirmed the possibility of suffering from nephrotic syndrome after receiving the vaccine.⁽¹⁰⁹⁾ Other publications also documented adverse reactions to this vaccine.^{(110-111-112-113-114-115-116-117-118-119)}

France has eliminated antihepatitis B from the pediatric vaccination calendar

In July 1998, approximately 15.000 French citizens belonging to fifteen associations filed a lawsuit against the French government alleging that it had misled the public about the risks and benefits associated with the hepatitis B vaccine. Hundreds - perhaps thousands - of people had suffered autoimmune diseases and neurological disorders, including multiple sclerosis, after vaccination.⁽¹²⁰⁾ As a result, in October 1998 France became the first country to abolish the requirement for this vaccine to be admitted to school.⁽¹²¹⁾

The hepatitis B AIDS vaccine

In 1978 the New York Blood Center in Manhattan, New York, injected homosexual men with an experimental vaccine against hepatitis B, produced by Merck, for the preparation of which chimpanzees were used. Shortly thereafter, male homosexuals in San Francisco, Los Angeles, Denver, Chicago, and St. Louis also received 3 doses of the drug over a three-month period.
In 1980, 20% of gay men who volunteered for the Manhattan experiment tested positive for HIV - the highest incidence in the world, including Africa. In 1981, the AIDS epidemic became official. Although there is no evidence that the experimental hepatitis B vaccine in those homosexual volunteers caused AIDS, there is no doubt that the disease peaked soon after the shots.⁽¹²²⁾

How effective is the hepatitis B vaccine?

The effectiveness of the hepatitis B vaccine was defined by injecting the drug into subjects on whom the specific antibodies produced in the blood were then measured. These antibodies must meet or exceed certain levels established by experts and which are presumed to provide protection. Scientists call it "seroprotection." According to this definition, the vaccine is considered "highly immunogenic" when antibody levels are measurable in the short period after the last dose of a three-booster cycle.⁽¹²³⁾ Yet, according to the manufacturing industries, the duration of the protective effect in healthy vaccinated people is not known. Follow-up studies as early as five to nine years later show that about half of all vaccinated subjects no longer have protective levels of antibodies.^(124-125)

For example, a study published in the New England Journal of Medicine found that after five years, antibody levels (which are presumed to be linked to immunity) had dropped dramatically or were no longer detectable in 42% of those vaccinated. Furthermore, 34 of the 773 subjects (4,4%) were infected with the virus.^(126-127) In another study, fewer than 40% of those vaccinated had protective antibodies after five years.⁽¹²⁸⁾

Similar research showed that 48% of vaccinated subjects had inadequate antibody levels after just four years.⁽¹²⁹⁾ According to the WHO, up to "60% of adults will lose all measurable antibodies induced by the hepatitis B vaccine within six to ten years."⁽¹³⁰⁾ and the medical literature is full of data confirming the failure of vaccination.^(131-132)